Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Science

• Publication date

  2008-03-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/science.1153629PMID 18323416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CARMA1 Coiled-coil Domain Is Involved in the Oligomerization and Subcellular Localization of CARMA1 and Is Required for T Cell Receptor-induced NF-κB Activation*

  2007cited by this paper
• The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes

  2006cited by this paper
• Quantitative measurement of nuclear translocation events using similarity analysis of multispectral cellular images obtained in flow.

  2006cited by this paper
• A loss-of-function RNA interference screen for molecular targets in cancer

  2006cited by this paper
• Phosphorylation of the CARMA1 linker controls NF-kappaB activation.

  2005cited by this paper
• Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NF-kappaB activation.

  2005cited by this paper
• The biology of human lymphoid malignancies revealed by gene expression profiling.

  2005cited by this paper
• Phosphorylation of the CARMA1 Linker Controls NF-κB Activation

  2005cited by this paper
• CARMA1, BCL-10 and MALT1 in lymphocyte development and activation

  2004cited by this paper
• Mice lacking the CARD of CARMA1 exhibit defective B lymphocyte development and impaired proliferation of their B and T lymphocytes.

  2003cited by this paper
• Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

  2003cited by this paper
• The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

  2003cited by this paper
• The MAGUK family protein CARD11 is essential for lymphocyte activation.

  2003cited by this paper
• Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis.

  2003cited by this paper
• Requirement for CARMA1 in antigen receptor-induced NF-kappa B activation and lymphocyte proliferation.

  2003cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• IκB Kinase Signaling Is Essential for Maintenance of Mature B Cells

  2002cited by this paper
• A requirement for CARMA1 in TCR-induced NF-κB activation

  2002cited by this paper
• PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling.

  2002cited by this paper
• A requirement for CARMA1 in TCR-induced NF-kappa B activation.

  2002cited by this paper
• The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

  2002cited by this paper
• PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling

  2002cited by this paper
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

  2002cited by this paper
• Coiled coils: a highly versatile protein folding motif.

  2001cited by this paper
• Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells

  2001cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

  1997cited by this paper
• In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death.

  1997cited by this paper
• A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project

  1997cited by this paper

• Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies.

  2026cites this paper
• Low frequency and rare coding variants affect susceptibility and progression of childhood acute lymphoblastic leukemia

  2026cites this paper
• RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.

  2026cites this paper
• Targeting signaling pathways in lymphoma: From molecular mechanisms to clinical breakthroughs.

  2026cites this paper
• Mechanisms of resistance to bruton’s tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways

  2026cites this paper
• BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies.

  2025cites this paper
• Potentiation of noncanonical NF-κB signaling and marginal zone B cell expansion by CARD11-mediated regulation of p100 processing

  2025cites this paper
• Successful Treatment with Sirolimus of a Patient with a Novel CARD11 Germline Mutation in B-Cell Expansion with Nuclear Factor Kappa B and T-Cell Anergy: Case Report and Literature Review

  2025cites this paper
• CEACAM1 as a mediator of B-cell receptor signaling in mantle cell lymphoma

  2025cites this paper
• Pathway‐level mutational signatures predict breast cancer outcomes and reveal therapeutic targets

  2025cites this paper
• Targeting Lymphoma With Benzoxazole Derivatives: Effects on Viability and Protein Expression in Cell Lines

  2025cites this paper
• A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma

  2025cites this paper
• Feedback loops in B-cell chromatin regulation as a therapeutic target for modulating antibody production and malignancies: insights from BACH2.

  2025cites this paper
• CARD11 signaling regulates CD8+ T cell tumoricidal function

  2025cites this paper
• A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells

  2025cites this paper
• MALT1 Inhibitors and Degraders: Strategies for NF-κB-Driven Malignancies.

  2025cites this paper
• Berberine as a natural immunomodulator of B lymphocytes

  2025cites this paper
• B cell lymphocytosis and reprogramming due to bi-allelic CARD11 mutations.

  2025cites this paper
• Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy

  2025cites this paper
• Common origins of autoimmune diseases and lymphoid malignancies.

  2025cites this paper
• Neue Therapiestrategien beim primären ZNS-Lymphom

  2025cites this paper
• BENTA Disease or CARD11 Gain-of-Function? A Novel Variant with Atypical Features and a Literature Review.

  2025cites this paper
• Integrative genomic analysis identifies novel causal genes of Hodgkin’s and non-Hodgkin’s lymphoma

  2025cites this paper
• Long‐term laboratory Drosophila populations show flexible plasticity in response to ancestral nutritional cues

  2025cites this paper
• Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051

  2025cites this paper
• Audit of B-cell cancer genes

  2025cites this paper
• QRICH1 mediates an intracellular checkpoint for CD8+ T cell activation via the CARD11 signalosome.

  2025cites this paper
• Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy.

  2024cites this paper
• Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma

  2024cites this paper
• Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma

  2024cites this paper
• TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma

  2024cites this paper
• A Rare Case of Primary Vulvar Diffuse Large B‐Cell Lymphoma: A Case Report

  2024cites this paper
• Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma

  2024cites this paper
• CARD11 regulates the thymic Treg development in an NF-κB-independent manner

  2024cites this paper
• A new-disease-causing dominant-negative variant in CARD11 gene in a Chinese case with recurrent fever

  2024cites this paper
• Bioinformatic analysis of molecular characteristics and oncogenic features of CARD14 in human cancer

  2024cites this paper
• MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma

  2024cites this paper
• Successful treatment of hemophagocytic intravascular large B-cell lymphoma with CNS involvement with BTK inhibitor combined with rituximab and high-dose methotrexate

  2024cites this paper
• Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma

  2024cites this paper
• Ibrutinib and R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma of non-GCB type: Phase II clinical trial of the Spanish GELTAMO group.

  2024cites this paper
• First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma

  2024cites this paper
• Genomic landscape and distinct molecular subtypes of primary testicular lymphoma

  2024cites this paper
• Advances in biology, diagnosis and treatment of DLBCL

  2024cites this paper
• Identification of Immune-Related Gene Pair Signature to Predict Prognosis of Diffuse Large B-Cell Lymphoma Based on Bioinformatics Analyses

  2024cites this paper
• Comparative analysis of somatic mutations in MYD88, CD79B, CARD11, and BTK between gastric marginal zone B-cell lymphoma of MALT and diffuse large B-cell lymphoma

  2024cites this paper
• Enforced CARD11/MALT1 signaling in dendritic cells triggers hemophagocytic lymphohistiocytosis

  2024cites this paper
• Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics

  2024cites this paper
• Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL

  2024cites this paper
• Prognostic Significance of T-Cells and Macrophages in the Tumour Microenvironment of Nodal DLBCL

  2024cites this paper
• SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection

  2024influential citation
• Sending positive signals and good (calcium) vibes.

  2024cites this paper
• FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling

  2024cites this paper
• The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma

  2024cites this paper
• CARD14 signalosome formation is associated with its endosomal relocation and mTORC1-induced keratinocyte proliferation

  2024cites this paper
• Lymphomas of the Vulva: A Review of the MITO Rare Cancer Group

  2024cites this paper
• CARD11 gain of function upregulates BCL2A1 and promotes resistance to targeted therapies combination in B-cell lymphoma.

  2023cites this paper
• Genetic screening in a Brazilian cohort with inborn errors of immunity

  2023cites this paper
• Fibrin-associated large B-cell lymphoma shows frequent mutations related to immune surveillance and PTEN.

  2023cites this paper
• Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas.

  2023cites this paper
• A case of cold agglutinin syndrome associated with chronic lymphocytic leukaemia harbouring mutations in CARD11 and KMT2D

  2023cites this paper
• Potential role of the P2X7 receptor in the proliferation of human diffused large B-cell lymphoma

  2023cites this paper
• Diagnosis and Molecular Pathology of Lymphoblastic Leukemias and Lymphomas in the Era of Genomics and Precision Medicine: Historical Evolution and Current Concepts—Part 3: Mature Leukemias/Lymphomas

  2023cites this paper
• The Histopathology of Cold Agglutinin Disease-Associated B-Cell Lymphoproliferative Disease.

  2023cites this paper
• Function and targeting of MALT1 paracaspase in cancer.

  2023cites this paper
• Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas

  2023cites this paper
• Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas

  2023cites this paper
• MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas

  2023cites this paper
• Dynamic phosphatase-recruitment controls B-cell selection and oncogenic signaling

  2023cites this paper
• CARD11 gain-of-function mutation drives cell-autonomous accumulation of PD-1+ ICOShigh activated T cells, T-follicular, T-regulatory and T-follicular regulatory cells

  2023influential citation
• Chimeric and mutant CARD9 constructs enable analyses of conserved and diverged autoinhibition mechanisms in the CARD-CC protein family

  2023cites this paper
• Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors

  2023cites this paper
• Ferroptosis-related STEAP3 acts as predictor and regulator in diffuse large B cell lymphoma through immune infiltration

  2023cites this paper
• Molecular classification and therapeutics in diffuse large B-cell lymphoma

  2023cites this paper
• Cancer organoids: A platform in basic and translational research

  2023cites this paper
• Canine Somatic Mutations from Whole-Exome Sequencing of B-Cell Lymphomas in Six Canine Breeds—A Preliminary Study

  2023cites this paper
• Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL

  2023influential citation
• Rétrovirus humains T-lymphotropes

  2023cites this paper
• Biological heterogeneity in diffuse large B-cell lymphoma.

  2023cites this paper
• Role and application of chemokine CXCL13 in central nervous system lymphoma

  2023cites this paper
• miR‐17‐92 cluster‐BTG2 axis regulates B‐cell receptor signaling in mantle cell lymphoma

  2023cites this paper
• Neue Therapiestrategien beim primären Lymphom des Zentralnervensystems

  2023cites this paper
• Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma

  2023influential citation
• Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications

  2023cites this paper
• Mistuned NF-κB signaling in lymphocytes: lessons from relevant inborn errors of immunity.

  2023cites this paper
• Genomics Driving Diagnosis and Treatment of Inborn Errors of Immunity with Cancer Predisposition.

  2022cites this paper
• USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B‐cell lymphoma

  2022cites this paper
• Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells

  2022cites this paper
• Hyper-IgE and Carcinoma in CADINS Disease

  2022cites this paper
• Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis

  2022influential citation
• Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study

  2022cites this paper
• The Paracaspase MALT1 in Cancer

  2022cites this paper
• 3D-QSAR, drug-likeness, ADMET prediction, and molecular docking studies in silico of novel 5-oxo-1-thioxo-4,5-dihydro-1H-thiazolo[3,4-a]quinazoline derivatives as MALT1 protease inhibitors for the treatment of B cell lymphoma

  2022cites this paper
• Application of CRISPR-Based Technology in Medical Research and Disease Treatment

  2022cites this paper
• Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas

  2022cites this paper
• NF-κB Signaling Pathway and Efficacy of Bortezomib-Based Combination Chemotherapy in Patients with Non-Hodgkin's Lymphoma

  2022cites this paper
• CARMA3: A potential therapeutic target in non-cancer diseases

  2022cites this paper
• Lymphoma‐associated mutations in autoreactive memory B cells of patients with Sjögren's syndrome

  2022cites this paper
• CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma

  2022cites this paper
• Transforming mutations in the development of pathogenic B cell clones and autoantibodies *

  2022cites this paper
• Expanding spectrum, intrafamilial diversity, and therapeutic challenges from 15 patients with heterozygous CARD11-associated diseases: A single center experience

  2022cites this paper